Tag Archive | "Ranbaxy"

Merger completed between Ranbaxy and Sunpharma

Tags: , , , ,


Mumbai, India: March 25, 2015 – Sun Pharmaceutical Industries Ltd., begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth. Read the full story

Partnering Agreements with Ranbaxy

Tags: ,


The Partnering Agreements with Ranbaxy report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. Read the full story

Ranbaxy

Tags: , ,


Ranbaxy Laboratories is a top pharmaceutical company based in Haryana, India Read the full story

Sun Pharma and Ranbaxy engage in M&A transaction

Tags: , , ,


Sun Pharmaceutical agreed to m&a transaction to buy competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo, which paid 61 percent more for the company five years ago. Read the full story

Ranbaxy: One of the world’s fastest growing pharmaceuticals companies

Tags: , ,


Ranbaxy is a research based pharmaceutical company with a strong focus on developing generics. Read the full story

Ranbaxy: Partnering activity 2009-2014

Tags: , , ,


Ranbaxy, a research based big pharma company with its headquarters in India, has announced 14 partnering / licensing deals since 2009, with 5 deals in 2010 alone. Read the full story

Ranbaxy retains exclusivity for Diovan

Tags: ,


Indian pharma major Ranbaxy is likely to announce a tie-up with a multinational company for sourcing active pharmaceutical ingredient (API) for its blood pressure drug- Diovan. Read the full story

Ranbaxy Laboratories also looking to sell its vaccine business

Tags: , ,


Drug maker Ranbaxy Laboratories is likely to sell off Biovel, a Bangalore-based vaccine manufacturing company which it had acquired in 2010. Read the full story

Ranbaxy: Company Profile

Tags: ,


Ranbaxy Laboratories, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story